Prevalence of Mupirocin Resistance in Patients Colonized with Staphylococcus Aureusin A Tertiary Care Rural Hospital

Title: Prevalence of Mupirocin Resistance in Patients Colonized with Staphylococcus Aureusin A Tertiary Care Rural Hospital

Authors: Dardi Charan Kaur, Nidhi Sharma, Pandey Aastha N

DOI: https://dx.doi.org/10.18535/jmscr/v4i11.23

Abstract

Introduction: Nasal carriage of Staphylococcus aureus plays a key role in the epidemiology and pathogenesis of infection and is a major risk factor for the development of both community-acquired and nosocomial infections. A causal relationship between S. aureus nasal carriage and infection is supported by the fact that the nasal strain and the infecting strain share the same genotype. Nasal mupirocin, a nasal formulation is approved by the United States Food and Drug Administration for eradicating nasal carriage in patients as well as in health care personnel. The increasing prevalence of mupirocin resistance among Staphylococcus aureus & coagulase-negative Staphylococcus (CoNS) species could be an important threat to the future use of mupirocin against MRSA. Thus this study was carried out with the aimsto know the prevalence of mupirocin resistance in Patients colonized with Staphylococcus spp.

Methodology: A total of 229 hospitalised patients were randomly selected. S. aureus &CoNS isolates were tested for mupirocin resistance by the disk diffusion method using 5µg and 200µg mupirocin discs.

Results: Out of 229 hospitalised patients, MRSA was isolated in 21(9.17%) and MRCoNS in 27(11.79 %). 5(2.18%) isolates were Mupirocin resistance.

Low-Level Mupirocin resistance (MuL) was seen in 1(0.44%) of MRSA and High-Level mupirocin resistance (MuH) was noted in 4(1.74%) isolates of MRCoNS

Conclusion: The presence of mupirocin resistance in 1(0.44%) of MRSA and 4(1.74%) of MRCoNS is a cause of concern. Hence it is recommended that routine testing of MRSA for mupirocin resistance be conducted.

Keyword- Nasal carriage, MRSA, MRCoNS, Mupirocin resistance.

References

1. Cookson D. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J AntimicrobChemother1998; 41:11-8.

2. Zierdt CH. Long term Staphylococcus aureus carrier state in hospital patients. J ClinMicrobiol1982; 16:517-20.

3. Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect 1995; 31:13–24.

4. Von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 2001; 344:11–6.

5. Corne P, Marchandin H, Jonquet O, Campos J, Banuls AL. Molecular evidence that nasal carriage of Staphylococcus aureus plays a role in respiratory tract infections of critically ill patients. J ClinMicrobiol2005; 43:3491–3.

6. Jones JC, Rogers TJ, Brookmeyer P, Dunne WM, Jr., Storch GA, Coopersmith CM, et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis. 2007;45(5):541-7.

7. Sousa-Junior FC, Silva-Carvalho MC, Fernandes MJ, Vieira MF, Pellegrino FL, Figueiredo AM, et al. Genotyping of methicillin-resistant Staphylococcus aureus isolates obtained in the Northeast region of Brazil. Braz J Med Biol Res. 2009;42(10):877-81.

8. Kluytmans J, Belkum A, Verbrugh H. Nasal Carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms, and associated risks. ClinMicrobiol Rev1997; 10: 505-520.

9. Palepou MF, Johnson AP, Cookson BD, et al. Evaluation of disc diffusion and E-test for determining the susceptibility of Staphylococcus aureus to mupirocin. J AntimicrobChemother 1998:42:577–83.

10. Laupland KB, Conly JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin:an evidenced-based review. Clin Infect Dis. 2003; 37:933-8.

11. Rahaman M, Noble WC, Cookson B. Mupirocin-resistant Staphylococcus aureus. Lancet. 1987; 2:387-8.

12. Morehouse E, Fenelon L, Hone R. Staphylococcus aureus sensitivity to various antibiotics- a national survey of Ireland 1993. Irish J Med Sci 1996; 165:40-3.

13. Upton A, Lang S, Hefferman H. Mupirocin and Staphylococcus aureus: A recent paradigm of emerging antibiotic resistance of Antimicrobial Chemother 2003; 51:613-7.

14. Vasquez JE, Walker ES, Franzus BW, Overbay BK, Reagan DR, SarubbiFA.The epidemiology of mupirocin resistance among methicillin-resistant Staphyloco-ccus aureus at a veteran's affair hospital. Infect Control HospEpidemiol 2000; 21:459-64.

15. Udo, E. L. Jacob,B. Mathew. 2001. Genetic analysis of methicillin-resistant Staphylococcus aureus expressing high- and low-level mupirocin resistance. J. Med. Microbiol.50:909-915.

16. Christine Seah, David C. Alexander, Lisa Louie, Andrew Simor, Donald E. Low, Jean Longtin and Roberto G. Melano. MupB, a New High-Level Mupirocin Resistance Mechanism in Staphylococcus aureus. Antimicrob. Agents Chemother. 2012, 56(4):1916.

17. Simor AE, Phillips E, McGeer A, et al. Randomized controlled trial of chlorhexidinegluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 2007; 44:178–85.

18. Clinical and laboratory standard institute (2012). Performance standards for antimicrobial disc susceptibility tests, twentieth supplement. 32(3) M100- S21.

19. Finlay JE, Millar LA, Poupard JA. Interpretive criteria for testing susceptibility of staphylococci to mupirocin. Antimicrob Agents Chemother 1997; 41: 1137-9.

20. Yazgi H, Ertek M, Ozbek A, Kadanali A. Nasal carriage of Staphylococcus aureus in hospital personnel and the normal population and antibiotic resistance of the isolates. Mikrobiyol Bul. 2003 Apr-Jun; 37(2-3):137-42.

21. Halablab MA, Hijazi SM, Fawzi MA, Araj GF. Staphylococcus aureus nasal carriage rate and associated risk factors in individuals in the community. Epidemiol Infect. 2010; 138(5):702-6.

22. Adebayo O Shittu, Edet E Udo and Johnson Lin. Phenotypic and molecular characterization of Staphylococcus aureus isolates expressing low- and high-level mupirocin resistance in Nigeria and South Africa. BMC Infectious Diseases 2009, 9:10

23. Hurdle JG, O’Neill AJ, Mody L, Chopra I, Bradley SF. In vivo transfer of high-level mupirocin resistance from Staphylococcus epidermidis to methicillin-resistant Staphylococcus aureus associated with failure of mupirocin prophylaxis. J AntimicrobChemother 2005; 56:1166–8.

24. Bastos MC, Mondino PJ, Azevedo ML, Santos KR, Giambiagi-deMarval M. Molecular characterization and transfer among Staphylococcus strains of a plasmid conferring high-level resistance to mupirocin. Eur J ClinMicrobiol Infect Dis 1999; 18:393–8.

25. Tara Babu, VioletaRekasius, Jorge P. Parada, Paul Schreckenberger, Malliswari Challapalli. Mupirocin Resistance among Methicillin-Resistant Staphylococcus aureus-Colonized Patients at Admission to a Tertiary Care Medical Center.J Clin Microbiol. Jul 2009; 47(7): 2279–2280.

26. Jeffrey C. Jones,Theodore J. Rogers,Peter Brookmeyer,William Michael Dunne, Jr.,Gregory A. Storch, Craig M. Coopersmith et al.Mupirocin Resistance in Patients Colonized with Methicillin-Resistant Staphylococcus aureus in a Surgical Intensive Care Unit. Clinical Infectious Diseases 2007; 45:541–7

27. Vivoni AM, Santos KR, de-Oliveira MP, et al. Mupirocin for controlling methicillin-resistant Staphylococcus aureus: lessons from a decade of use at a university hospital. Infect Control Hosp Epidemiol 2005; 26:662–7.

Corresponding Author

Dardi Charan Kaur

Department of Microbiology, MIMER Medical College, Talegaon Dabhade, Pune

Mobile No: 09823817936, Fax No 02114- 223916

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.